Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Marilena Di Napoli is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 27 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome

Cecere, S. C., Giannone, G., Salutari, V., Arenare, L., Lorusso, D., Ronzino, G., Lauria, R., Cormio, G., Carella, C., Scollo, P., Ghizzoni, V., Raspagliesi, F., Di Napoli, M., Mazzoni, E., Marchetti, C., Bergamini, A., Orditura, M., Valabrega, G., Scambia, G., Maltese, G. & 7 others, De Matteis, E., Cardalesi, C., Loizzi, V., Boccia, S., Naglieri, E., Scandurra, G. & Pignata, S., 2020, In : Gynecologic Oncology.

Research output: Contribution to journalArticle

  • Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel

    Lorusso, D., Bologna, A., Cecere, S. C., De Matteis, E., Scandurra, G., Zamagni, C., Arcangeli, V., Artioli, F., Bella, M., Blanco, G., Cardalesi, C., Casartelli, C., De Vivo, R., Di Napoli, M., Gisone, E. B., Lauria, R., Lissoni, A. A., Loizzi, V., Maccaroni, E., Mangili, G. & 13 others, Marchetti, C., Martella, F., Naglieri, E., Parolin, V., Ricciardi, G., Ronzino, G., Salutari, V., Scarfone, G., Secondino, S., Spagnoletti, I., Tasca, G., Tognon, G. & Guarneri, V., Jan 1 2020, (Accepted/In press) In : Supportive Care in Cancer.

    Research output: Contribution to journalArticle

  • PARP inhibitors in ovarian cancer

    Franzese, E., Centonze, S., Diana, A., Carlino, F., Guerrera, L. P., Di Napoli, M., De Vita, F., Pignata, S., Ciardiello, F. & Orditura, M., 2019, In : Cancer Treatment Reviews. 73, p. 1-9 9 p.

    Research output: Contribution to journalReview article

  • The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer

    MITO Investigators, Jun 2019, In : Gynecologic Oncology. 153, 3, p. 535-540 6 p.

    Research output: Contribution to journalArticle